This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.
The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.
GCA is a chronic and potentially life-threatening autoimmune condition and Actemra/RoActemra’s approval was based on data from the phase III GiACTA study. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to
Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks
Sarilumab is a fully human monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6 receptors, and is the first direct competitor to Roche's Actemra/RoActemra (tocilizumab)
Any delay to the programme is however a blow to Sanofi and Regeneron, which are playing catch-up against the only marketed IL-6 inhibitor - Roche's Actemra/RoActemra (tocilizumab) - while
Meanwhile, Roche's interleukin-6 inhibitor RoActemra/Actemra (tocilizumab) picked up a BTD for giant cell arteritis, a chronic and potentially life-threatening autoimmune condition in which serious inflammation is seen
More from news
Approximately 5 fully matching, plus 21 partially matching documents found.
Campaign:RoACTEMRA / ACTEMRA: beyond the boundaries of existing treatments. Timescale:2008 to 2009. ... Online monitoring tools tracked RoACTEMRA / ACTEMRA noise, identifed top influencers and tonality of digital conversations.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market
leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...